(Q37354836)

19 August 2017

1 reference

title

Drug development from marine natural products (English)

1 reference

19 August 2017

main subject

marine natural product

0 references

1 reference

Doralyn S Dalisay

2

0 references

author name string

Tadeusz F Molinski

series ordinal

1

1 reference

19 August 2017

Sarah L Lievens

series ordinal

3

1 reference

19 August 2017

Jonel P Saludes

series ordinal

4

1 reference

19 August 2017

publication date

19 December 2008

1 reference

Nature Reviews Drug Discovery

19 August 2017

published in

1 reference

19 August 2017

volume

8

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

69-85

1 reference

Marine natural products and related compounds in clinical and advanced preclinical trials

19 August 2017

cites work

1 reference

Natural products as sources of new drugs over the last 25 years

31 March 2020

1 reference

The evolving role of natural products in drug discovery

31 March 2020

1 reference

Peptide neurotoxins from fish-hunting cone snails

31 March 2020

1 reference

Conus venoms: a rich source of novel ion channel-targeted peptides

31 March 2020

1 reference

Calcium channel diversity and neurotransmitter release: the omega-conotoxins and omega-agatoxins

31 March 2020

1 reference

Roles of individual disulfide bonds in the stability and folding of an omega-conotoxin

31 March 2020

1 reference

Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom

31 March 2020

1 reference

Structural and dynamic characterization of omega-conotoxin MVIIA: the binding loop exhibits slow conformational exchange

31 March 2020

1 reference

Tyr13 is essential for the activity of omega-conotoxin MVIIA and GVIA, specific N-type calcium channel blockers

31 March 2020

1 reference

Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega-conopeptide MVIIC)

31 March 2020

1 reference

Characterization of the binding of omega-conopeptides to different classes of non-L-type neuronal calcium channels

31 March 2020

1 reference

Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus

31 March 2020

1 reference

Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain

31 March 2020

1 reference

Ziconotide: neuronal calcium channel blocker for treating severe chronic pain

31 March 2020

1 reference

Peptide leads new class of chronic pain drugs

31 March 2020

1 reference

Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata

31 March 2020

1 reference

Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinata

31 March 2020

1 reference

Additional antitumor ecteinascidins from a Caribbean tunicate: crystal structures and activities in vivo

31 March 2020

1 reference

Enantioselective Total Synthesis of Ecteinascidin 743

31 March 2020

1 reference

A New, More Efficient, and Effective Process for the Synthesis of a Key Pentacyclic Intermediate for Production of Ecteinascidin and Phthalascidin Antitumor Agents

31 March 2020

1 reference

Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B

31 March 2020

1 reference

Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action

31 March 2020

1 reference

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

31 March 2020

1 reference

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove

31 March 2020

1 reference

The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent

31 March 2020

1 reference

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

31 March 2020

1 reference

Life expectancy as an indicator of outcome in follow-up of population-based cancer registries: the example of childhood leukemia

31 March 2020

1 reference

Phase II Study of Trabectedin in Pretreated Patients with Advanced Colorectal Cancer

31 March 2020

1 reference

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

31 March 2020

1 reference

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

31 March 2020

1 reference

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

31 March 2020

1 reference

Therapeutic impact of ET-743 (Yondelis; trabectidin), a new marine-derived compound, in sarcoma

31 March 2020

1 reference

Progress in the clinical development of new marine-derived anticancer compounds.

31 March 2020

1 reference

A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.

31 March 2020

1 reference

A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours

31 March 2020

1 reference

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies

31 March 2020

1 reference

Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft

31 March 2020

1 reference

In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction

31 March 2020

1 reference

Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro

31 March 2020

1 reference

Hepatotoxicity and metabolism of trabectedin: a literature review.

31 March 2020

1 reference

Natural products as probes of cell biology: 20 years of didemnin research

31 March 2020

1 reference

Didemnins: Antiviral and Antitumor Depsipeptides from a Caribbean Tunicate

31 March 2020

1 reference

Crystal and molecular structure of didemnin B, an antiviral and cytotoxic depsipeptide

31 March 2020

1 reference

The antiproliferative agent didemnin B uncompetitively inhibits palmitoyl protein thioesterase

31 March 2020

1 reference

Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis

31 March 2020

1 reference

Mechanism of action of didemnin B, a depsipeptide from the sea

31 March 2020

1 reference

Mechanism of protein synthesis inhibition by didemnin B in vitro

31 March 2020

1 reference

Inhibition of protein synthesis by didemnin B: how EF-1alpha mediates inhibition of translocation

31 March 2020

1 reference

Structural basis for the binding of didemnins to human elongation factor eEF1A and rationale for the potent antitumor activity of these marine natural products

31 March 2020

1 reference

Inhibition of protein synthesis by didemnin B is not sufficient to induce apoptosis in human mammary carcinoma (MCF7) cells

31 March 2020

1 reference

Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine

31 March 2020

1 reference

Protein tyrosine kinase inhibitors prevent didemnin B-induced apoptosis in HL-60 cells

31 March 2020

1 reference

Rapamycin inhibits didemnin B-induced apoptosis in human HL-60 cells: evidence for the possible involvement of FK506-binding protein 25

31 March 2020

1 reference

Didemnins A and B. Effectiveness against cutaneous herpes simplex virus in mice

31 March 2020

1 reference

Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates

31 March 2020

1 reference

Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide

31 March 2020

1 reference

Application of a new preclinical drug screening system for cancer of the large bowel

31 March 2020

1 reference

Didemnin B induces cell death by apoptosis: the fastest induction of apoptosis ever described

31 March 2020

1 reference

Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays

31 March 2020

1 reference

A phase I clinical trial of didemnin B

31 March 2020

1 reference

Phase I clinical study of didemnin B. A National Cancer Institute of Canada Clinical Trials Group study

31 March 2020

1 reference

Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting

31 March 2020

1 reference

Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer

31 March 2020

1 reference

Phase II clinical trial of didemnin B in previously treated small cell lung cancer

31 March 2020

1 reference

Didemnin B in favourable histology non-Hodgkin's lymphoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group

31 March 2020

1 reference

Phase II trail of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) Study

31 March 2020

1 reference

A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an Eastern Cooperative Oncology Group study (PB687)

31 March 2020

1 reference

Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319).

31 March 2020

1 reference

Phase II study of Didemnin B in central nervous system tumors: a Southwest Oncology Group study

31 March 2020

1 reference

Pharmaceutical development of anticancer agents derived from marine sources

31 March 2020

1 reference

Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta

31 March 2020

1 reference

Mitochondrial cytochrome c release is caspase-dependent and does not involve mitochondrial permeability transition in didemnin B-induced apoptosis

31 March 2020

1 reference

Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK.

31 March 2020

1 reference

JNK activation is critical for Aplidin-induced apoptosis.

31 March 2020

1 reference

Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.

31 March 2020

1 reference

VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia.

31 March 2020

1 reference

Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin

31 March 2020

1 reference

Effect of Aplidin in acute lymphoblastic leukaemia cells.

31 March 2020

1 reference

In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results

31 March 2020

1 reference

Didemnin B induces apoptosis in proliferating but not resting peripheral blood mononuclear cells

31 March 2020

1 reference

In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: a rational basis for clinical development

31 March 2020

1 reference

Antiangiogenic activity of aplidine, a new agent of marine origin

31 March 2020

1 reference

Hemiasterlin and geodiamolide TA; two new cytotoxic peptides from the marine sponge Hemiasterella minor (Kirkpatrick)

31 March 2020

1 reference

Cytotoxic peptides from the marine sponge Cymbastela sp.

31 March 2020

1 reference

Cytotoxic and tubulin-interactive hemiasterlins from Auletta sp. and Siphonochalina spp. sponges.

31 March 2020

1 reference

Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation

31 March 2020

1 reference

Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1

31 March 2020

1 reference

Synthesis and antimitotic/cytotoxic activity of hemiasterlin analogues

31 March 2020

1 reference

Synthesis and biological activity of analogues of the antimicrotubule agent N,beta,beta-trimethyl-L-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]- N(1),3-dimethyl-L-valinamide (HTI-286).

31 March 2020

1 reference

D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitors

31 March 2020

1 reference

Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment

31 March 2020

1 reference

Tubulin inhibitors. Synthesis and biological activity of HTI-286 analogs with B-segment heterosubstituents

31 March 2020

1 reference

Probing the interaction of HTI-286 with tubulin using a stilbene analogue

31 March 2020

1 reference

Biophysical Characterization of the Interactions of HTI-286 with Tubulin Heterodimer and Microtubules

31 March 2020

1 reference

Localization of the antimitotic peptide and depsipeptide binding site on beta-tubulin

31 March 2020

1 reference

Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin

31 March 2020

1 reference

Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability

31 March 2020

1 reference

Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin

31 March 2020

1 reference

(+)-discodermolide: a marine natural product against cancer.

31 March 2020

1 reference

Immunosuppression by discodermolide.

31 March 2020

1 reference

Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissoluta

31 March 2020

1 reference

Distinct binding and cellular properties of synthetic (+)- and (-)-discodermolides

31 March 2020

1 reference

Total synthesis of the potent microtubule-stabilizing agent (+)-discodermolide

31 March 2020

1 reference

Total synthesis of (+)-discodermolide: an improved endgame exploiting a Still-Gennari-type olefination with a C1-C8 beta-ketophosphonate fragment

31 March 2020

1 reference

A second-generation total synthesis of (+)-discodermolide: the development of a practical route using solely substrate-based stereocontrol

31 March 2020

1 reference

Gram-scale synthesis of (+)-discodermolide

31 March 2020

1 reference

A practical improvement, enhancing the large-scale synthesis of (+)-discodermolide: a third-generation approach

31 March 2020

1 reference

(+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest

31 March 2020

1 reference

Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol

31 March 2020

1 reference

The Microtubule-Stabilizing Agent Discodermolide Competitively Inhibits the Binding of Paclitaxel (Taxol) to Tubulin Polymers, Enhances Tubulin Nucleation Reactions More Potently than Paclitaxel, and Inhibits the Growth of Paclitaxel-Resistant Cells

31 March 2020

1 reference

Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells

31 March 2020

1 reference

Discodermolide interferes with the binding of tau protein to microtubules.

31 March 2020

1 reference

Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function.

31 March 2020

1 reference

The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence

31 March 2020

1 reference

Discodermolide analogues as the chemical component of combination bacteriolytic therapy

31 March 2020

1 reference

Pharmaceuticals from cultured algae

31 March 2020

1 reference

Total Structures of Cryptophycins, Potent Antitumor Depsipeptides from the Blue-Green Alga Nostoc sp. Strain GSV 224

31 March 2020

1 reference

Arenastatin A, a potent cytotoxic depsipeptide from the Okinawan marine sponge Dysidea arenaria

31 March 2020

1 reference

Cryptophycin-induced hyperphosphorylation of Bcl-2, cell cycle arrest and growth inhibition in human H460 NSCLC cells

31 March 2020

1 reference

Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site

31 March 2020

1 reference

Interaction of cryptophycin 1 with tubulin and microtubules

31 March 2020

1 reference

Mechanism of action cryptophycin. Interaction with the Vinca alkaloid domain of tubulin

31 March 2020

1 reference

Mechanism of Action of the Unusually Potent Microtubule Inhibitor Cryptophycin 1

31 March 2020

1 reference

In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines

31 March 2020

1 reference

Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule.

31 March 2020

1 reference

Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer

31 March 2020

1 reference

Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors

31 March 2020

1 reference

The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10

31 March 2020

1 reference

Progress in the discovery of biosynthetic anticancer drugs

31 March 2020

1 reference

Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain

31 March 2020

1 reference

Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules

31 March 2020

1 reference

A steroid derivative with paclitaxel-like effects on tubulin polymerization

31 March 2020

1 reference

Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer

31 March 2020

1 reference

Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium

31 March 2020

1 reference

Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer

31 March 2020

1 reference

Phase II trial of dolastatin-10 in patients with advanced breast cancer

31 March 2020

1 reference

Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers

31 March 2020

1 reference

Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy

31 March 2020

1 reference

Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.

31 March 2020

1 reference

Halichondrins - antitumor polyether macrolides from a marine sponge

31 March 2020

1 reference

Norhalichondrin A: an antitumor polyether macrolide from a marine sponge

31 March 2020

1 reference

: Isolation and structure of halistatin 1 from the eastern Indian Ocean marine sponge Phakellia carteri

31 March 2020

1 reference

Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp.

31 March 2020

1 reference

Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin.

31 March 2020

1 reference

The discovery and development of marine compounds with pharmaceutical potential

31 March 2020

1 reference

Structure-activity relationships of halichondrin B analogues: modifications at C.30-C.38.

31 March 2020

1 reference

Kahalalide F: a bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp

31 March 2020

1 reference

Kahalalides: Bioactive Peptides from a Marine Mollusk Elysia rufescens and Its Algal Diet Bryopsis sp.(1)

31 March 2020

1 reference

Hassallidin A, a glycosylated lipopeptide with antifungal activity from the cyanobacterium Hassallia sp.

31 March 2020

1 reference

Chemical defenses of the sacoglossan mollusk Elysia rufescens and its host Alga bryopsis sp.

31 March 2020

1 reference

Synthesis and structure determination of kahalalide F (1,2).

31 March 2020

1 reference

Stereochemistry of kahalalide F

31 March 2020

1 reference

The antitumoral compound Kahalalide F acts on cell lysosomes

31 March 2020

1 reference

The mechanism of action of Kahalalide F: variable cell permeability in human hepatoma cell lines

31 March 2020

1 reference

Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F.

31 March 2020

1 reference

Preclinical toxicity studies of kahalalide F, a new anticancer agent: single and multiple dosing regimens in the rat.

31 March 2020

1 reference

Isolation and structure of bryostatin 1

31 March 2020

1 reference

The large-scale isolation of bryostatin 1 from Bugula neritina following current good manufacturing practices

31 March 2020

1 reference

Total Synthesis of Bryostatin 2

31 March 2020

1 reference

Synthesis of bryostatin 7

31 March 2020

1 reference

Synthesis of the bryostatin 1 northern hemisphere (C1-C16) via desymmetrization by ketalization/ring-closing metathesis

31 March 2020

1 reference

Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C

31 March 2020

1 reference

Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin

31 March 2020

1 reference

Chemistry and clinical biology of the bryostatins

31 March 2020

1 reference

A phase II study of bryostatin 1 in metastatic malignant melanoma

31 March 2020

1 reference

Phase II study of bryostatin 1 in patients with relapsed multiple myeloma

31 March 2020

1 reference

The clinical development of the bryostatins

31 March 2020

1 reference

Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study

31 March 2020

1 reference

A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.

31 March 2020

1 reference

Phase II evaluation of bryostatin-1 in metastatic melanoma

31 March 2020

1 reference

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

31 March 2020

1 reference

A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma.

31 March 2020

1 reference

Targeting the cell cycle: a new approach to cancer therapy

31 March 2020

1 reference

Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry

31 March 2020

1 reference

Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinispora tropica

31 March 2020

1 reference

New drugs from marine microbes: the tide is turning

31 March 2020

1 reference

Privileged structures as leads in medicinal chemistry.

31 March 2020

1 reference

bryA: an unusual modular polyketide synthase gene from the uncultivated bacterial symbiont of the marine bryozoan Bugula neritina

31 March 2020

1 reference

Identification of the putative bryostatin polyketide synthase gene cluster from "Candidatus Endobugula sertula", the uncultivated microbial symbiont of the marine bryozoan Bugula neritina

31 March 2020

1 reference

Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.

31 March 2020

1 reference

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

31 March 2020

1 reference

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

31 March 2020

1 reference

Phorboxazoles A and B: potent cytostatic macrolides from marine sponge Phorbas species

31 March 2020

1 reference

Absolute configuration of phorboxazoles A and B from the marine sponge, Phorbas sp. 2. C43 and complete stereochemistry

31 March 2020

1 reference

Chlorocyclopropane macrolides from the marine sponge Phorbas sp. assignment of the configurations of phorbasides A and B by quantitative CD.

31 March 2020

1 reference

Phorbasides A-E, cytotoxic chlorocyclopropane macrolide glycosides from the marine sponge Phorbas sp. CD determination of C-methyl sugar configurations

31 March 2020

1 reference

A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma

31 March 2020

1 reference

12 December 2020

Inhibition by Aplidine of the aggregation of the prion peptide PrP 106–126 into β-sheet fibrils

1 reference

12 December 2020

A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.

1 reference

12 December 2020

Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days

1 reference

12 December 2020

Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs

1 reference

12 December 2020

Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity.

1 reference

12 December 2020

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative

1 reference

12 December 2020

Modulation of gene expression in the acute promyelocytic leukemia cell line NB4.

1 reference

12 December 2020

Determination of disulfide bridge pattern in omega-conopeptides.

1 reference

12 December 2020

Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia

1 reference

12 December 2020

Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat

1 reference

12 December 2020

Conus toxins: targets and properties

1 reference

12 December 2020

Late activation of apoptotic pathways plays a negligible role in mediating the cytotoxic effects of discodermolide and epothilone B in non-small cell lung cancer cells.

1 reference

12 December 2020

Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas

1 reference

12 December 2020

Discodermolide: just another microtubule-stabilizing agent? No! A lesson in synergy

1 reference

12 December 2020

HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.

1 reference

12 December 2020

Effect of bryostatin 1 on the in vitro radioprotective capacity of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) toward committed human myeloid progenitor cells (CFU-GM)

1 reference

12 December 2020

Salinispora arenicola gen. nov., sp. nov. and Salinispora tropica sp. nov., obligate marine actinomycetes belonging to the family Micromonosporaceae

1 reference

12 December 2020

Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma

1 reference

12 December 2020

Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells.

1 reference

12 December 2020

Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.

1 reference

12 December 2020

Transmitter release from presynaptic terminals of electric organ: inhibition by the calcium channel antagonist omega Conus toxin

1 reference

12 December 2020

GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha

1 reference

12 December 2020

Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.

1 reference

12 December 2020

Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors

1 reference

12 December 2020

Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain.

1 reference

12 December 2020

Bacterial symbionts: prospects for the sustainable production of invertebrate-derived pharmaceuticals

1 reference

12 December 2020

Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C

1 reference

12 December 2020

Phase Ib trial of bryostatin 1 in patients with refractory malignancies

1 reference

12 December 2020

Total Synthesis of Bryostatin 3

1 reference

12 December 2020

The chemistry and biology of discodermolide

1 reference

12 December 2020

1 reference

12 December 2020

Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer

1 reference

12 December 2020

Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.

1 reference

12 December 2020

Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines.

1 reference

12 December 2020

Antitumor compounds from tunicates

1 reference

12 December 2020

In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells

1 reference

12 December 2020

Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling.

1 reference

12 December 2020

Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent

1 reference

12 December 2020

TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply.

1 reference

12 December 2020

In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity

1 reference

12 December 2020

Discodermolide--a new, marine-derived immunosuppressive compound. I. In vitro studies

1 reference

12 December 2020

Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites

1 reference

12 December 2020

Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors

1 reference

12 December 2020

Discodermolide--a new, marine-derived immunosuppressive compound. II. In vivo studies

1 reference

12 December 2020

Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data

1 reference

12 December 2020

Rapid and selective apoptosis in human leukemic cells induced by Aplidine through a Fas/CD95- and mitochondrial-mediated mechanism.

1 reference

12 December 2020

In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B

1 reference

12 December 2020

Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation

1 reference

12 December 2020

Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.

1 reference

12 December 2020

Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD2487

1 reference

19 August 2017

1 reference